Views: 6 Author: Site Editor Publish Time: 2021-02-17 Origin: Site
What are the common pharmaceutical intermediates? Pharmaceutical intermediates refer to chemical raw materials or chemical products used in the pharmaceutical synthesis process. From the perspective of the development history of China's pharmaceutical intermediate industry, after nearly 30 years of development, pharmaceutical intermediates have evolved from a small branch of the chemical industry into an emerging industry with billions of dollars in output value, and their market competition has become increasingly fierce. The following editors will introduce you to several common pharmaceutical intermediates:
N-benzyl-N-methylethanolamine is an important pharmaceutical intermediate that can synthesize anti-asthma and anti-allergy drugs, antihypertensive drug nicardipine and some new drugs for the treatment of cardiovascular diseases; in addition, it can also synthesize pesticide herbicides and plants Fungicides and metal preservatives.
Methyl 4,4’-dimethoxyacetoacetate is an important intermediate for the treatment of cardiovascular and cerebrovascular diseases, Nilvadipine, and is currently the leading therapeutic drug for cardiovascular and cerebrovascular diseases in the international market. Glyoxylic acid is used as the raw material to synthesize trimethyl orthoformate in the presence of concentrated sulfuric acid to obtain methyl dimethoxyacetate. ester.
α-methylene cyclic ketone
Alpha-methylene cyclic ketone is the active center of many drugs with anti-cancer activity, which contains α, β-unsaturated ketone structure, which is a hidden group of anti-cancer active groups, and has become an important synthesis of many important cyclic anti-cancer drugs Intermediate.
4-Propylthio-o-phenylenediamine is a key intermediate of the highly effective broad-spectrum deworming drug albendazole. Albendazole is a new drug marketed in the late 1980s. Imidazole drugs have the strongest medicinal properties.
Pazopanib is a new oral angiogenesis inhibitor developed by GlaxoSmithKline that can interfere with the neovascularization required for the survival and growth of stubborn tumors, targeting vascular endothelial growth factor receptor (VEGFR), It works by inhibiting the formation of new blood vessels that supply blood to tumors. It is suitable for the treatment of advanced renal cell carcinoma (a type of kidney cancer in which cancer cells are found in renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer, and non-small cell lung cancer (NSCLC).
Bosutinib, developed by Wyeth Pharmaceuticals, was approved by the EU in September 2010 as an "orphan drug" for the treatment of chronic myeloid leukemia (CML). On September 4, 2012, the drug was approved for marketing by the US Food and Drug Administration (FDA) under the brand name Bosulif. The European Food and Drug Administration (EMA) endorsed the market on March 27, 2013, and the PMDA endorsement on the market in Japan on September 26, 2014.